Avadel Pharmaceuticals plc (AVDL)
$
9.05
-0.01 (-0.11%)
Key metrics
Financial statements
Free cash flow per share
-0.2633
Market cap
906.4 Million
Price to sales ratio
4.6616
Debt to equity
0.0391
Current ratio
2.7341
Income quality
0.9558
Average inventory
20.4 Million
ROE
-0.3607
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States, primarily focusing on the development of innovative treatments for sleep disorders. Its lead product candidate, FT218, is a formulation of sodium oxybate currently undergoing a Phase 3 clinical trial aimed at treating excessive daytime sleepiness and cataplexy in adults diagnosed with narcolepsy. The company was previously known as Flamel Technologies SA until its rebranding as Avadel Pharmaceuticals plc in January 2017. Incorporated in 2015 and headquartered in Dublin, Ireland, Avadel Pharmaceuticals has reported depreciation and amortization expenses of $2,681,000.00 which highlight the wear and tear of its assets. Additionally, the company achieved a revenue of $169,117,000.00 underscoring its niche market focus. With an income before tax of -$49,079,000.00 the organization demonstrates pre-tax profitability. Furthermore, its operating income ratio is -$0.25 which indicates the company’s operational profitability margin, reflecting its effective management and strategic positioning in the biopharmaceutical arena. The company's stock is identified by the symbol '$AVDL' in the market, marking its presence among investors. Investing in Avadel Pharmaceuticals could be a strategic move, as the stock is affordable at $9.05 making it suitable for budget-conscious investors. The stock has a high average trading volume of 1,097,921.00 indicating strong liquidity, which could facilitate easier entry and exit for investors. With a market capitalization of $875,486,991.00 the company is classified as a small-cap player, positioning it competitively in the industry landscape. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market trajectory, and it belongs to the Healthcare sector, driving innovation and growth within its fields. This unique positioning not only highlights the potential for future expansion but also reinforces the company's role as an important contributor to healthcare advancements, cultivating interest among potential investors looking to support impactful biopharmaceutical initiatives.
Is Avadel Pharmaceuticals plc (AVDL) a good investment?
Investing in Avadel Pharmaceuticals plc (AVDL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Avadel Pharmaceuticals plc (AVDL)'s stock forecast?
Analysts predict Avadel Pharmaceuticals plc stock to fluctuate between $6.38 (low) and $17.30 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Avadel Pharmaceuticals plc's market capitalization?
As of 2025-05-28, Avadel Pharmaceuticals plc's market cap is $875,486,991, based on 96,738,894 outstanding shares.
How does Avadel Pharmaceuticals plc compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Avadel Pharmaceuticals plc has a Lower Market-Cap, indicating a difference in performance.
How can I buy Avadel Pharmaceuticals plc (AVDL) stock?
To buy Avadel Pharmaceuticals plc (AVDL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AVDL. Place an order (Market, Limit, etc.).
What is the best time to invest in Avadel Pharmaceuticals plc?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Avadel Pharmaceuticals plc perform in the last earnings report?
Revenue: $169,117,000 | EPS: -$0.51 | Growth: -74.50%.
Where can I find Avadel Pharmaceuticals plc's investor relations reports?
Visit https://www.avadel.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Avadel Pharmaceuticals plc?
You can explore historical data from here
What is the all-time high and low for Avadel Pharmaceuticals plc stock?
All-time high: $19.09 (2024-05-03) | All-time low: $1.05 (2022-05-26).
What are the key trends affecting Avadel Pharmaceuticals plc stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
seekingalpha.com
Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter the idiopathic hypersomnia market after a favorable court ruling. Analysts remain bullish, reiterating Buy ratings and projecting significant revenue and profit growth through FY2026 as LUMRYZ adoption accelerates.
zacks.com
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zacks.com
The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
seekingalpha.com
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Mark Goodman - Leerink David Huang - Deutsche Bank Myriam Belghiti - LSC Ami Fadia - Needham Chase Knickerbocker - Craig Hallum Operator Greetings, and welcome to Avadel Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all participants are in a listen only mode.
globenewswire.com
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) has ruled in favor of Avadel, overturning important parts of the injunction imposed by the U.S. District Court for the District of Delaware (the “Delaware Court”) regarding LUMRYZ™ as a potential treatment of indications beyond narcolepsy. The Federal Circuit vacated the portion of the injunction that prohibited Avadel from applying for FDA approval of LUMRYZ for any indication beyond narcolepsy, calling the district court's analysis “simply too speculative and tenuous.
globenewswire.com
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
seekingalpha.com
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Austin Murtagh - Precision AQ Gregory Divis - Chief Executive Officer Thomas McHugh - Chief Financial Officer Conference Call Participants François Brisebois - Oppenheimer Poorna Kannan - Needham & Company Oren Livnat - H.C. Wainwright & Co. David Amsellem - Piper Sandler & Co. Madhumita Yennawar - Leerink Partners Myriam Belghiti - LifeSci Capital David Hoang - Deutsche Bank AG Brandon Folkes - Rodman & Renshaw Research Operator Greetings, and welcome to Avadel Pharmaceuticals' Fourth Quarter and Business Update Conference Call.
See all news
